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The human gamma herpesviruses, Kaposi sarcoma-associated
virus (KSHV) and EBV, are associated with multiple cancers. Recent
evidence suggests that EBV and possibly other viruses can
manipulate the tumor microenvironment through the secretion
of specific viral and cellular components into exosomes, small
endocytically derived vesicles that are released from cells. Exo-
somes produced by EBV-infected nasopharyngeal carcinoma cells
contain high levels of the viral oncogene latent membrane protein
1 and viral microRNAs that activate critical signaling pathways in
recipient cells. In this study, to determine the effects of EBV and
KSHV on exosome content, quantitative proteomics techniques
were performed on exosomes purified from 11 B-cell lines that are
uninfected, infected with EBV or with KSHV, or infected with both
viruses. Using mass spectrometry, 871 proteins were identified, of
which ∼360 were unique to the viral exosomes. Analysis by 2D
difference gel electrophoresis and spectral counting identified
multiple significant changes compared with the uninfected control
cells and between viral groups. These data predict that both EBV
and KSHV exosomes likely modulate cell death and survival, ribo-
some function, protein synthesis, and mammalian target of rapa-
mycin signaling. Distinct viral-specific effects on exosomes suggest
that KSHV exosomes would affect cellular metabolism, whereas
EBV exosomes would activate cellular signaling mediated through
integrins, actin, IFN, and NFκB. The changes in exosome content
identified in this study suggest ways that these oncogenic viruses
modulate the tumor microenvironment and may provide diagnos-
tic markers specific for EBV and KSHV associated malignancies.
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Microvesicles are membrane-enclosed vesicles secreted fromcells that participate in intracellular communication events
through the transfer of biologically active proteins, lipids, and
RNAs (1). Perhaps the best-studied class of microvesicles is
exosomes which are 40- to 100-nm vesicles that originate from
internal endosomal-derived membranes of multivesicular bodies
(MVBs). Upon fusion of MVBs with the cell surface, exosomes
are released into the extracellular space and can be taken up by
neighboring cells, degraded, or enter connecting bodily fluids
and travel to distal sites within the body. To date, exosomes have
been found in almost every bodily fluid and increasingly are
evaluated for their potential as diagnostic biomarkers. Exosomes
are thought potentially to modulate many physiological pro-
cesses including development, cell growth, immune regulation,
angiogenesis, neuronal communication, cell migration, and in-
vasion (1). Accumulating evidence supports the hypothesis that
disruption of or alterations in normal exosome function may
contribute to disease pathogenesis, and unique properties have
been identified in exosomes released from malignant cells.
The human gamma herpesviruses, Kaposi sarcoma-associated
virus (KSHV) and EBV, are considered the etiologic agents for
several lymphoid malignancies (2–4). EBV is associated with
Burkitt lymphoma, Hodgkin lymphoma, posttransplantation
lymphoproliferative diseases, and AIDS-associated lymphomas,
whereas KSHV is found in all primary effusion lymphomas
(PELs) and multicentric Castleman’s disease. A subset of PELs
contains both KSHV and EBV (5). Previous studies have shown
that EBV affects exosome content and function, and virally
modified exosomes can contain the viral oncoproteins latent
membrane proteins 1 and 2 (LMP1 and LMP2) and virally
encoded microRNAs (miRNAs) (6, 7). The transfer of LMP1-
containing exosomes induces the activation of phosphoinositide
3-kinase (PI3K)/AKT and MAPK/ERK pathways in target cells
(6). Additionally, exosomal transfer of EBV miRNAs has been
shown to reduce target gene expression in recipient cells (8).
Therefore, EBV-infected cells can modulate the cellular micro-
environment through the transfer of virally modified exosomes.
This transfer may be a significant mechanism through which her-
pesviruses maintain a latent and persistent infection within the
host. Additionally, it is likely that tumorigenic herpesviruses such as
EBV and KSHV modulate exosome content and function so that
exosomes produced by the infected cells affect the tumor micro-
environment and contribute to cancer progression.
Multiple studies have begun to define the protein, RNA, and
lipid components of exosomes secreted from various cell types
(9–11). In this study, exosomes were purified from EBV-infected,
KSHV-infected, and dually infected B-cell lines and were ana-
lyzed using quantitative proteomics approaches to determine how
EBV and KSHV infection alters B-cell exosome components.
Mass spectrometry analysis of purified exosomes from 11 dif-
ferent B-cell lines revealed 871 proteins. Data from spectral
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counting determined that the B-cell exosome proteome from the
virally infected cells was significantly different from the exosomes
produced by the uninfected B-cell control exosomes, with 345
proteins unique to the virally infected cells and with significant
changes specific to each virus. These data show that EBV and
KSHV potently affect the host exosome pathway.
Results
Viral Expression and Exosome Purification. The type of latent in-
fection in the EBV-infected cells was determined by evaluating
expression of Epstein–Barr nuclear antigen 2 (EBNA2) and
LMP1, considered indicative of Type III latency (12). EBNA2
was detected readily in #1, HLJ, and CP cell lines and at lower
levels in IM9 cells but was not detected in the KSHV-infected or
dually infected lines. A background band with a higher molecular
weight was detected at varying levels in all cell lines tested
(Fig. 1A, asterisk). LMP1 was detected in the four EBV+ cell lines
(a smaller form was detected consistently in CP cells), whereas
LMP2 was detected in #1 and CP cells. The dually infected
KSHV+/EBV+ cell lines did not express these viral proteins.
Dually infected PEL cell lines have been shown previously to
lack expression of these EBV proteins and are considered rep-
resentative of Type I latency, which frequently is found in Burkitt
lymphoma (Fig. 1A). Latency-associated nuclear antigen (LANA)
was detected in all KSHV cell lines (Fig. 1A). Exosomes were
purified using a sucrose cushion from the conditioned media of
various B-cell lines, either uninfected (BJAB cell line) or infec-
ted with EBV, KSHV, or EBV and KSHV. The purity of the
exosome preparations was determined by electron microscopy
(EM) and immunoblot analysis for exosome specific markers.
EM images of the preparations did not detect any virions but did
reveal many membrane-enclosed vesicles with sizes ranging from
40–100 nm that exhibited the typical cup-shaped morphology
previously described for exosomes after negative staining (Fig.
1B). Multiple exosome-specific markers were detected by im-
munoblot analysis of exosome lysates (Fig. 1C). Interestingly, the
levels of some exosome markers varied among the cell lines,
suggesting that viral infection could alter exosome components.
Ezrin, a protein previously shown to be up-regulated by LMP1,
was significantly increased in EBV+/LMP1+ exosomes compared
with the uninfected BJAB control cells (Fig. 1C) (13). Addition-
ally, Flotillin 2, a major lipid raft resident protein, was increased
in LMP1+ exosomes (14, 15). LMP1 traffics to and alters the
components of lipid rafts for signal transduction (16, 17) and
therefore may contribute to exosomal targeting of lipid raft pro-
teins such as Flotillin 2 (18). LMP1 was detected by immuno-
blotting in exosomes isolated from all four EBV-infected B cells
at levels approximately proportional to those found in whole-cell
lysates (Fig. 1C). LMP2 was detected in exosomes from one of the
LMP2+ cell lines (Fig. 1C). These data indicate that both EBV-
and KSHV-infected B cells secrete microvesicles with biophysical
and biochemical properties consistent with exosomes.
Mass Spectrometric Analyses. To determine the effect of viral in-
fection on exosome content, purified exosome proteins were
separated by strong anion-exchange and reverse-phase chroma-
tography before mass spectrometry. Data analysis following
multidimensional protein identification technology (19) un-
covered a total of 871 specific proteins throughout all B-cell
exosome lines (Dataset S1). Of these 871 proteins detected in all
preparations of B-cell exosomes, 569 were present in the Exo-
carta database of published exosome proteomic results, including
21 of the 25 most frequently identified proteins (11). These data
confirm that the preparations do indeed contain abundant levels
of exosomes. The mass spectrometry analysis also uncovered 302
newly identified exosome components not present in Exocarta as
indicated by Venn diagram (Fig. 2A and Dataset S1). Inter-
estingly of the 302 proteins uniquely identified in this study, 164
had significantly (P ≤ 0.05) altered levels because of virus in-
fection as compared with the uninfected control cell line (BJAB)
(Dataset S1). Viral proteins were not identified in this unbiased
mass spectrometry analysis, which is based on the 15 most in-
tense peptide ion peaks for MS/MS during a mass spectrometry
acquisition cycle. These findings indicate that proteins repre-
senting potential virion contamination of the exosome prepara-
tions were below the threshold of detection for MS/MS.
Presentation of the distinct exosome protein content accord-
ing to the infection status of the B-cell lines indicated that of the
871 total proteins identified, 449 were common to uninfected
BJAB B-cell exosomes and EBV- or KSHV-infected exosomes
(Fig. 2B and Dataset S2). As anticipated, latent herpesvirus in-
fection significantly altered exosome content; 230 proteins were
identified in both EBV and KSHV exosomes that were not
present in the uninfected exosomes, 93 proteins were specific to
EBV-infected exosomes and 22 were specific to the KSHV exo-
somes (Fig. 2B). An additional 16 distinct proteins were present in
the dually infected cell lines that were not detected in the un-
infected control cells (Dataset S2). Many of the differences de-
termined between exosome groups are likely to be specific to viral
infection; however, some may be unique to the BJAB exosomes.
Comparison of the exosomes from the KSHV-, EBV-, and
dually infected cell lines indicated that the virus-modified exo-
somes had 631 proteins affected in common (Fig. 2C). The EBV
exosomes had multiple additional changes, with 91 uniquely
identified components, whereas 41 changes were detected in the
exosomes from KSHV or dually infected cells, including 23
proteins that were present in both the KSHV-infected and
KSHV/EBV dually infected exosomes, six proteins specific for
the KSHV exosomes, and 12 proteins found only in the dually
infected exosomes (Fig. 2C and Dataset S2). These data further
support the hypothesis that virus infection has major effects on
exosome content and that these changes likely modulate their
functional properties.
2D Gel Electrophoresis. To confirm the potential viral-specific
differences in exosome content, 2D difference gel electropho-
resis (2D DIGE) was used (20). Changes in protein-expression
levels in B-cell exosomes revealed by 2D-DIGE were analyzed
using DeCyder software which identified 2,131 protein spots
matched across all gels (for a representative gel, see Fig. 3A). A
t-test analysis of LMP1+ versus LMP1− cell lines revealed 217
Fig. 1. Characterization of exosomes secreted from B cells. (A) Whole-cell
lysates from various B-cell lines that were uninfected (BJAB), EBV infected
(#1, HLJ, IM9, CP), KSHV infected (JC, BCBL1, BCP1, BC3), or dually infected
(BC1 and JSC-1) were separated by SDS/PAGE and analyzed by immunoblot
analysis for the indicated proteins. GAPDH was used as a loading control. (B)
Exosomes were purified from the conditioned media of the B cells and an-
alyzed by electron microscopy. Representative images of exosomes produced
from the IM9 and BC1 cell lines are shown. (C) Lysates from purified exo-
somes were separated by SDS/PAGE and analyzed by immunoblot for ex-
pression of indicated viral proteins and common exosome markers. Asterisks
indicate a with a higher molecular weight detected using EBNA2 antibody.
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protein spots with significantly different expression (P < 0.05).
When cell lines were grouped according to infection type, dif-
ferential expression analysis (ANOVA) revealed 209 protein
spots with significantly different expression (P < 0.05).
These protein spot differences were examined further by
principal component analysis (PCA) and hierarchical cluster
analysis using the DeCyder software (Fig. 3). In the PCA of
LMP1+ versus LMP1− data (Fig. 3B), principal component 1
(PC1), which contained 58.8% of the variance between samples,
confirmed that the expression of EBV infection with LMP1 ex-
pression represented the dominant component affecting the
grouping of B-cell line exosomes. The second principle compo-
nent (PC2), with 15.7% of variance, was primarily between the
uninfected BJAB control cells and all other (infected) cell lines.
When the cell lines were grouped according to infection differ-
ences, PCA revealed that PC1, containing 56.9% of the variance,
was found between EBV alone and other types of infection (Fig.
3C). PC2, with 19.4% of variance, was primarily between KSHV-
infected and the dually infected cell lines. In contrast, EBV-
infected B-cell lines showed little influence of PC2, as shown by
their proximity to the PC2 axis. Similarly, hierarchical cluster
analysis (Fig. 3D) grouped B-cell exosomes into three distinct
branches (clusters) representing the type of infection (i.e., EBV,
KSHV, or dual infection). EBV infection alone produced the
most distinct cluster, with these B-cell lines branching off first
from the KSHV- and dually infected lines. Interestingly, these
exosomes also branched within the distinct EBV cluster based on
LMP1 expression levels in the producing cell lines. KSHV- and
dually infected lines also segregated as a second branching event
(Fig. 3D).
Label-Free Spectral Count-Based Quantitative Proteomic Analysis. To
evaluate further the exosome proteome changes caused by virus
infection, the grouped virally modified exosome proteins were
analyzed by spectral counting with changes represented relative
to the uninfected BJAB exosomes (21). Regardless of the in-
fection types compared, ∼21% of the B-cell exosome proteome
was altered. The levels of 187 of the 871 proteins identified in the
dataset were altered significantly (P ≤ 0.05; Fisher’s exact t-test)
in exosomes secreted from EBV-infected cells (Dataset S1, in-
dicated in yellow). Similar numbers of changes also were ob-
served with KSHV (188 of 871) or KSHV+EBV (207 of 871)
infection as compared with uninfected BJAB exosomes (Dataset
S1). Ezrin, which was not detected by immunoblotting in the
BJAB exosomes, also was not detected by liquid chromatography
tandem mass spectrometry (LC-MS/MS) in BJAB exosomes.
However, it was detected in all the exosome preparations from
the virally infected cell lines. Thus, ezrin is indicated with an
Fig. 2. Venn diagrams of proteins identified in B-cell exosomes by mass
spectrometry. (A) The total number of proteins identified throughout all
B-cell exosome samples was compared with results from the entire Exocarta
database of published exosome proteomics. (B) Exosome components identi-
fied from the EBV- or KSHV-infected cells were compared with those found
in the uninfected BJAB control cell line. (C) Comparison of proteins specific
to each infection type and those proteins common to infection types.
Fig. 3. 2D DIGE and Decyder analysis of B-cell exosome proteomes. Exosomal proteins were labeled with fluorescent dyes and separated by 2D DIGE in pH
3–10 immobilized gradients and SDS 12.5% polyacrylamide gels. (A) Representative gel shown (1 of 10) with IM9 exosome proteins labeled with Cy3 (green)
and BC-3 exosome proteins labeled with Cy5 (red). PCA was performed on the 2D DIGE data and plotted based on (B) LMP1 expression or (C) viral groups.
(D) Hierarchical cluster analysis of significantly (P ≤ 0.05, ANOVA) altered exosome components grouped by viral infection status. Red lines represent proteins
whose expression levels were up-regulated relative to the group, green lines represent down-regulated proteins, and black lines represent unchanged
proteins. The red triangle depicts relative LMP1 expression in the EBV cell lines.























infinite fold change with P values of 4.2 × 10−6 for the EBV
exosomes and 0.015 for KSHV exosomes (Dataset S1).
Unbiased hierarchical clustering analysis of the differentially
expressed exosome components separated the samples into
groups based on virus infection, confirming the 2D-DIGE anal-
yses. The unique clustering pattern and variable levels of EBNA2
and LMP2 in the cell lines suggested that LMP1 was a major
factor in the induction of specific changes in exosome content.
Major differences in expression correlated highly with Type 3
latency and levels of LMP1 expression, with LMP1− exosomes
isolated from EBV and KSHV-infected PELs clustering dis-
tinctly from those isolated from the EBV-infected, LMP1-
expressing lymphoblastoid cell lines (LCLs) (Fig. 4 A and B).
These data further indicate that EBV and KSHV have distinct
effects on exosome content. In EBV-infected cells, Type III la-
tency and LMP1 expression are major factors contributing to the
changes in exosome content, whereas the exosomes produced by
the cells dually infected with EBV and KSHV are closely linked
to those from KSHV-infected cells. This result suggests that the
highly restricted EBV infection within the dually infected PEL
does not have a major effect beyond KSHV on exosome content.
However, the two cell lines did group distinctly, and 12 proteins
were detected only in exosomes from the dually infected cells,
which also contained 54 proteins that were significantly altered
compared with BJAB cells (Fig. 2C and Dataset S1).
To enhance the statistical power of the analyses the quanti-
tative mass spectrometry, data from each individual cell line
were grouped into either LMP1+ or LMP1− datasets. In this
analysis, the exosomes from the EBV/KSHV dually infected cells
are grouped with the KSHV-infected cell exosomes because they
lacked LMP1 expression. There were 358 significant changes
(P ≤ 0.05, Fisher’s exact t test) identified between the groups
with log twofold changes ranging from 5 to −2.5 (Fig. 5 and
Dataset S3). This analysis reveals that the LMP1− exosomes had
30% of the amount of ezrin contained in LMP1+ exosomes (Fig.
5 A and B). There also were 60 proteins present in LMP1+
exosomes not found in LMP1− exosomes and were given an ar-
bitrary fold change of 5 (log2) (Fig. 5C and Dataset S3). Inter-
estingly, more of the significantly altered proteins were increased
in LMP1+ exosomes than in LMP1− exosomes (Fig. 5C and
Dataset S3). This difference may reflect the specific recruitment
of protein complexes into exosomes and the potent effects of
LMP1 on cellular protein expression.
Viral-Specific Effects. The cellular proteins that were specifically
up-regulated in the EBV+ LMP1+ exosomes included multiple
HLA class I and class II proteins (Fig. 5 A and B). LMP1 has
been shown to up-regulate HLA proteins, and their enriched
secretion into exosomes may modulate viral entry or immune
recognition (22–24). Furthermore, the EBV/LMP1 exosomes
contained multiple kinases including the TNF receptor-associ-
ated factor 2 and NF-κB–inducing kinase (TNIK) (25), the fgr
kinase, which has been linked to EBV infection (26), and the
protein 85 (p85) regulatory subunit of PI3K, a protein recently
shown to be induced into lipid rafts by LMP1 expression (16).
Additional proteins previously shown to be up-regulated by
LMP1, including intercellular adhesion molecule 1 and ezrin, also
were increased in the EBV exosomes (13, 27) (Figs. 1A and B
and Dataset S3). Other exosome components potentially reg-
ulated by LMP1 include proteins involved with membrane and
protein trafficking [annexins, Rab GTPases, and ADP-ribosylation
factor 6 (ARF6)], binding (integrins), lipid rafts (Flotillin 1 and 2),
and signaling [growth factor receptor-bound protein 2 (GRB2),
NRAS, LYN, MAPK1, RAC2, and phosphatidylinositol-5-phos-
phate 4-kinase type-2 alpha (PIP4K2A)] (Fig. 5 A and B and
Datasets S1 and S2). These findings support previous studies that
have indicated functional effects of EBV exosomes on signaling
and immune function (6, 28–30).
The exosome components from KSHV-infected PEL with
P values <0.05 are indicated in yellow in Dataset S1 with fold
increase in comparison with exosomes from uninfected BJAB
cell. Although histones previously have been shown to be present
in exosomes from different cell types (31), the exosomes from
KSHV-infected PEL cells showed a preferential increase in
many histone proteins including histones H1, H2A, H2B, H3,
H4, and variants of each of these core histones as compared with
BJAB cells (Dataset S1) or EBV LCLs (LMP1+) (Fig. 5 A and
B). Additionally, several enzymes involved with glycolysis also
were significantly up-regulated in PEL exosomes compared with
Fig. 4. Hierarchical clustering of B-cell exosome proteins. (A) Unsupervised hierarchical clustering of B-cell exosome proteins that show up-regulation in
EBV-infected B-cell lines as determined by spectral count-based quantitative proteomic analysis. (B) Unsupervised hierarchical clustering of B-cell exosome
proteins that show up-regulation in KSHV- or KSHV+EBV-infected cell lines that also were LMP1−.
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BJAB exosomes. These enzymes included pyruvate kinase, eno-
lase, phosphoglyceromutase, phosphoglycerate kinase, glycer-
aldehyde dehydrogenase, triose phosphate isomerase, fructose
biphosphate aldolase, phosphoglucose isomerase, and lactate
dehydrogenase. These data are concordant with other reports
showing KSHV-infected cells have increased glycolysis and
fatty acid synthesis (32–34). Therefore, it is conceivable that
exosomal transfer of glycolytic enzymes could enhance glycolysis
in recipient cells.
Factors involved in protein translation also were increased in
exosomes from KSHV-infected cells as compared with un-
infected BJAB exosomes. The 40S and 60S ribosomal subunits,
several different tRNA synthetases, as well as several translation
factors (e.g., Eukaryotic translation initiation factor 3) were in-
creased in exosomes from PEL compared with BJAB cells. This
increase may reflect the known effects of KSHV and some of its
viral proteins including K1 and viral G protein-coupled receptor,
which have been shown to modulate the cellular protein syn-
thesis machinery through activation of the PI3K/mammalian
target of rapamycin (mTOR) pathway (35–40). Of interest, up-
regulation of PI3K signaling also is involved in activation of
glycolysis by KSHV, as described above (32, 41). Moreover,
additional factors involved in cell migration (integrin alpha 6,
fibronectin, vitronectin, and collagen) and PI3K signaling (lym-
phocyte-specific protein tyrosine kinase) were found to be pref-
erentially up-regulated in the exosomes from KSHV-infected
cells (Fig. 5 A and B and Dataset S3).
Collectively, these data suggest that exosomes from KSHV-
infected B cells preferentially incorporate proteins involved in
metabolism, translation, migration, and chromatin modeling as
compared with uninfected B cells. This exclusive loading may
reflect alterations of these pathways within infected cells and
suggests that the secreted exosomal proteins from KSHV-infec-
ted cells could participate in paracrine or autocrine mechanisms.
Predicted Viral-Specific Effects on Exosome Content and Function. To
gain potential insight into how modulation of exosome compo-
nents may contribute to exosome function and potentially to
disease, the proteins that were only identified in the viral exo-
some preparations or that had significantly altered expression in
comparison with BJAB were analyzed with Ingenuity Pathway
Analysis (IPA) software (Fig. 6). The gene sets include the 230
virally induced genes (Fig. 2B and Dataset S2) that are unique to
the EBV and KSHV singly infected cell lines and that are not
present in the viral-negative BJAB cell line (Fig. 6A), the 264
genes significantly altered (P ≤ 0.05; Dataset S1) by KSHV and
KSHV/EBV (Fig. 6B), the 190 genes significantly altered (P ≤
0.05; Dataset S1) by KSHV alone (Fig. 6C), and the 358 genes
that are changed significantly (Dataset S3) when grouped by
LMP1 expression (Fig. 6D). Strikingly, IPA indicated that for all
four populations Cancer was the highest represented Diseases
and Disorder category (Fig. 6), and Cell Death and Survival was
the top Molecular and Cellular Function predicted to be af-
fected. The EBV/LMP1 exosomes also were enriched for pro-
teins that affect the Molecular and Cellular Functions of Cell
Growth and Proliferation, Cellular Movement, and Cell-to-Cell
Signaling. The Top Canonical Pathways had more variation
among groups, although all were enriched for genes predicted to
affect eukaryotic initiation factor 2 (EIF2) signaling. IPA also
predicted KSHV effects on glycolysis, gluconeogenesis, remod-
eling of adherens junctions, and clathrin-mediated endocytosis.
Confounding the interpretation of the IPA analysis is that gly-
colysis and glyconeogenesis are competing pathways. However,
the two pathways contain many of the same enzymes, which are
dimeric and can catalyze in both directions. The KSHV exo-
somes contained seven enzymes that participate in both path-
ways and additionally contained hexokinase, pyruvate kinase,
and lactose dehydrogenase, which are specific to glycolysis. En-
zymes specific for gluconeogenesis, such as glucose-6-phospha-
tase, fructose 1,6-biphosphatase, pyruvate carboxylase, and
phosphoenolpyruvate carboxykinase, were not detected in the
exosomes. The EBV/LMP1 exosomes were enriched for proteins
Fig. 5. Label-free spectral count-based quantitative proteomic analysis. (A)
Volcano plot showing normalized differences in protein expression in LMP1+
and LMP1− B-cell lines infected with EBV, KSHV, or EBV+KSHV. Note that the
ANOVA P value of 0.05 (−log10 = 1.3) is used to identify significant differ-
ences in protein expression. (B) Enlarged view of the region highlighted in
orange in A. (C) Overall differences in protein expression in LMP1+ and
LMP1− B-cell lines ranked by protein ID. (Insets) Number of down-regulated
and up-regulated proteins that show a log2 twofold change in the LMP1
+/
LMP1− ratio. Points marked in red represent proteins highlighted in A and B.
Infinity units were given arbitrary values of log2 5 and −2.5.























Fig. 6. IPA of virally modified exosome components. IPA of (A) proteins only identified within EBV and KSHV exosomes compared to the BJAB control, (B)
genes significantly altered by KSHV and KSHV/EBV relative to BJAB, (C) genes significantly altered by KSHV relative to BJAB, and (D) genes significantly
changed when grouped by LMP1 expression. The graphs for the top Diseases and Disorders (Left) and Molecular and Cellular Functions (Center) categories
show the total number of molecules identified by mass spectrometry that fall into the designated Ingenuity classification. The Top Canonical Pathways graphs
(Right) represent the ratio of the number of molecules identified in this study to the total number of proteins in each Ingenuity pathway.
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in Canonical Pathways that likely affect exosome formation and
uptake such as Caveolar-Mediated Endocytosis Signaling, Virus
Entry via Endocytic Pathway, Integrin Signaling, and Actin Cy-
toskeleton (Fig. 6).
Discussion
Exosomes’ potential roles in disease pathogenesis are increasingly
appreciated, and many studies are focusing on exosomes produced
by malignant cells as potential biomarkers. The data presented
here identify specific and global effects of the human oncogenic
viruses, EBV and KSHV, on exosome content. The data indicate
that exosome content is highly complex, with 871 proteins iden-
tified by LC-MS/MS, including more than 360 that were not
detected in the BJAB uninfected control cell line and that po-
tentially are unique to the viral exosomes. As the exosome pro-
teome is further defined, it is likely that many more intriguing
differences will be identified. For example, cluster of differenti-
ation 63 (CD63) and LMP1 were readily detected by immuno-
blotting of exosome preparations, even though neither protein
was identified by the mass spectrometry analysis. Based on the
proteins identified in this study, KSHV and EBV exosomes are
predicted to have multiple properties in common, with Cancer
identified as the predicted Disease and Disorder, Cell Death and
Survival as the commonly affected Cellular Function, and EIF2
Signaling as the commonly affected Canonical Pathway. These
findings suggest that both viruses affect exosome content to
modulate both cell death and protein synthesis. Additionally, the
viruses had distinct predicted effects on molecular and cellular
functions. Interestingly, many of the predicted modulated prop-
erties have been linked previously to the distinct viruses. KSHV
recently has been shown to reprogram the host B-cell metabolism
toward glycolysis, and the exosomes produced by the KSHV-
infected cells are highly enriched in proteins in the Glycolysis
Pathway. Importantly, it has been demonstrated experimentally
that overexpression of pyruvate kinase, lactate dehydrogenase,
or phosphoglucose isomerase increases glycolysis, and therefore
exosomal transfer of these enzymes also could modulate me-
tabolism in the recipient cells (42, 43). Intriguingly, the KSHV
exosomes also include proteins involved in remodeling epithelial
adherens junctions, suggesting that they may modulate cell an-
chorage or movement through these effects.
The 2D DIGE and the spectral counting and LC-MS/MS data
grouped the KSHV/EBV dually infected exosomes closely with
the KSHV exosomes and not with the EBV singly positive exo-
somes. These data indicate that the limited EBV expression in
the PEL cell lines has a lesser effect on exosome content than the
robust effects mediated in Type III latency with expression of
LMP1. However, PCA revealed that the dually infected cells are
distinct from the singly infected KSHV cells and the EBV-
infected cells (Fig. 3C). This difference may reflect the effect of
EBV functions that are expressed in the PEL lines, including
Epstein–Barr nuclear antigen 1 and the BamHI-A region (BART)
miRNAs, which are expressed at considerably higher levels in the
PEL cells than in most EBV-transformed B-cell lines (in which
BART miRNA expression is very low) (44).
The predicted Molecular Functions for the EBV+/LMP1+
exosomes are all cellular properties that have been shown to be
affected by LMP1. In various in vitro models LMP1 can induce
cellular growth and proliferation, modulate cell death and sur-
vival, activate cell-to-cell signaling, and induce cellular move-
ment (3). The Canonical Pathways predicted to be affected by
LMP1 expression in exosomes include Endocytosis, Cytoskeleton
Signaling, and Integrin Signaling. The effects on endocytosis may
be related to the enhanced binding and uptake described for
LMP1 exosomes, and it is known that LMP1 can induce actin
remodeling (6, 45). These data suggest that the functional prop-
erties of the exosomes may mimic many of the properties of
LMP1-expressing cells. Through its effects on exosome content,
LMP1 could influence these molecular functions or pathways in
both autocrine and paracrine mechanisms.
One mechanism through which virally modified exosomes
could affect these cellular functions is the transfer of biologically
active signal transduction components. Importantly, when the
significantly modified exosome components were analyzed within
IPA, many pathways were predicted to be activated by LMP1+
exosomes (Table S1). These pathways included several already
known to be regulated by LMP1 within infected cells, such as
protein 53 (P53), JAK/STAT, NFκB, interferon regulatory factor
7, and MAPK (Table S1). Interestingly, TNF and cluster of
differentiation 40 (CD40), cellular equivalents to LMP1, also
were predicted to be activated by LMP1+ exosomes. Constitutive
CD40 signaling phenocopies the transforming function of the
EBV oncoprotein LMP1 in vitro (46, 47). Insulin receptor sig-
naling, which activates the PI3K/AKT and rat sarcoma (Ras)/
MAPK pathways, two pathways affected by LMP1 signaling (16),
was predicted to be activated by LMP1+ exosomes. The identi-
fication of multiple signaling pathways that are predicted to be
activated confirms previous studies that have shown that LMP1+
expression alters exosome content so that LMP1+ exosomes in-
duce activation of ERK and AKT in recipient cells (6). Similarly,
the pathways predicted to be activated specifically by the
KSHV+ exosomes included MAPK1 and PI3K.
To look more closely at known LMP1-regulated pathways, the
dataset was overlaid with the ERK/MAPK, PI3K, and JAK/
STAT pathway within Ingenuity. As expected from the predicted
activated pathways, many exosome components also were pres-
ent in these pathways and were altered based on LMP1 expres-
sion. These included important upstream activators such as Ras,
FYN, LYN, p85 subunit of PI3K, ERK1/2, STAT, mTOR, and
GRB2 (Dataset S3). These data support the hypothesis that LMP1
modulates exosome content and that critical growth-inducing
pathways may be induced in recipients’ cells with the exosomal
transfer of LMP1 and other key cellular components (6).
The changes common to the exosome proteomes of both EBV
and KSHV indicate that both viruses target specific cellular
functions and that the altered exosomes likely modulate cell
death and survival with additional predicted effects on ribosome
function, protein synthesis, and mTOR signaling. Additionally,
the viruses have individual specific effects, with KSHV exosomes
predicted to modulate cellular metabolism and EBV exosomes
predicted to activate signaling mediated through integrins, actin,
IFN, and NFκB. It is clear that the virally infected cells can
manipulate the cellular microenvironment via exosomes and that
KSHV and EBV exosomes may have distinct effects on the re-
cipient cells. This activity is supported by the unique proteomes
of KSHV and EBV exosomes and previous studies that have
shown that exosomes released from EBV-infected epithelial cells
and lymphocytes can transfer their contents and modulate cel-
lular functions (6, 8). It is likely that these effects contribute to
viral persistence and pathogenesis.
Materials and Methods
Cells. B-cell lines were cultured in Roswell Park Memorial Institute (RPMI)
medium 1640 supplemented with 10% (vol/vol) FBS (Thermo), penicillin-
streptomycin (Gibco), antibiotic-antimycotic (Gibco), 0.075% sodium
bicarbonate, and 0.05 mmol/L 2-mercaptoethanol at 37 °C in 5% (vol/vol)
C02. The cell lines include EBV-infected LCLs (#1, HLJ, IM9, and CP), KSHV-
infected PELs (JC, BC3, BCP1, and BCBL1), and dually infected PELs (JSC-1
and BC1) (48, 49). The EBV-infected lines were established as spontaneous
transformed lines from peripheral blood samples. HLJ, CP, and JC cells were
kindly provided by Clio Rooney (Baylor College of Medicine, Houston, TX),
and #1 cells were obtained from Richard O’Reilly (Memorial Sloan–Kettering
Cancer Center, New York).
Exosome Purification. Cells were grown to an approximate concentration of
0.5 × 106 cells/mL in 100 mL of RPMI medium that was supplemented with
10% (vol/vol) exosome-depleted serum, antibiotics, 0.1% β-mercaptoethanol,























and sodium bicarbonate. The medium then was harvested and replaced with
150 mL of fresh RPMI medium, and the cells were grown for an additional
5 d. The conditioned medium was subjected to differential centrifugation of
480 × g for 5 min, 2,000 × g for 10 min, and 10,000 × g for 30 min and then
was filtered (0.2-uM pore size) and stored at 4 °C for up to 1 wk. To purify
exosomes, the medium was concentrated with a Centricon Plus-70 filter
(Millipore) according to the manufacturer’s instructions, placed over a 30%
(wt/vol) sucrose:deuterium oxide (D20) cushion (5 mL) in a SW32 polyallomer
tube (Beckman Coulter), and subjected to ultracentrifugation at 100,000 × g
for 1 h. After centrifugation, the sucrose cushion (∼4.75 mL) was removed
with a needle syringe without disturbing the pellet on the bottom of the
tube or the sucrose/medium interphase, and the medium was diluted
with 30 mL of PBS. The exosomes then were pelleted at 100,000 × g for
1 h, dissolved in lysis buffer [9 M Urea, 2 M Thiourea, 2% (wt/vol) 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate (CHAPS),
60 mM n-octyl-β-D-glucopyranocide, 30 mM Tris, pH8.5], and frozen at
−80 °C for proteomic analysis. To obtain enough protein for mass spec-
trometry (100 μg), exosomes preps were pooled from individual harvests
before digestion.
Protein Extraction and Digestion. Proteins were prepared for digestion using
the filter-assisted sample preparation method (50). Briefly, the sample was
brought to 2% (wt/vol) SDS, 50 mM Tris·HCl (pH 7.6), 10 mM DTT and was
heated at 95 °C for 10 min. Samples then were transferred to a 30,000 (30-k)
Vivaspin molecular weight cut off (MWCO) device (Vivaproducts) and
centrifuged at 13,000 × g for 10 min. The remaining sample was buffer
exchanged with 6 M urea, 100 mM Tris·HCl (pH 7.6) and then alkylated with
55 mM iodoacetamide. Concentrations were measured using a Qubit fluo-
rometer (Invitrogen). Trypsin was added at an enzyme-to-substrate ratio of
1:40, and the sample was incubated overnight on a heat block at 37 °C. The
device was centrifuged, and the filtrate was collected.
Peptide Desalting and Fractionation. Digested peptides were desalted using
C18 stop-and-go extraction (STAGE) tips (51). Briefly, for each sample a C18
STAGE tip was activated with methanol, and then conditioned with 60%
(vol/vol) acetonitrile, 0.5% acetic acid followed by 5% (vol/vol) acetonitrile,
0.5% acetic acid. Samples were loaded onto the tips and desalted with 0.5%
acetic acid. Peptides were eluted with 60% acetonitrile, 0.5% acetic acid and
vacuum centrifuged in a SpeedVac (Thermo Savant) for ∼1 h to a final vol-
ume of ∼5 μL.
Peptides were fractionated by strong anion exchange STAGE tip chro-
matography. Briefly, each sample was dissolved in Britton Robinson buffer,
pH 10, and loaded on to the STAGE tip. Flow-through was collected using
a C18 STAGE tip. Subsequent fractions were taken by eluting peptides with
Britton–Robinson buffers at pH 8, 6, 5, 4, and 3.2 and capturing with C18
STAGE tips. Peptides were eluted from the C18 STAGE tip and dried as
described above.
LC–MS/MS. Each fraction was analyzed by LC-MS/MS. LC was performed on an
Easy Nano LC II system (Thermo Scientific). Mobile phase A was 97.5% MilliQ
water, 2% (vol/vol) acetonitrile, 0.5% acetic acid. Mobile phase B was 90%
(vol/vol) acetonitrile, 9.5% MilliQ water, 0.5% acetic acid. The 120-min LC
gradient ran from 0% B to 35% B over 90 min, with the remaining time used
for sample loading and column regeneration. Samples were loaded to a trap
column, 2 cm × 75 μm i.d. The analytical column was 13 cm × 75 μm i.d. fused
silica with a pulled tip emitter. Both trap and analytical columns were
packed with 3 μm C18 resin (Magic C18AQ; Michrom). The LC system was
interfaced to a dual-pressure linear ion trap mass spectrometer (LTQ Velos;
Thermo Fisher) via nano-electrospray ionization. An electrospray voltage of
1.8 kV was applied to a precolumn tee. The mass spectrometer was pro-
grammed to acquire, by data-dependent acquisition, tandem mass spectra
from the top 15 ions in the full scan from 400–1400 m/z.
Mass Spectrometry Data Processing. Mass spectra were processed, and pep-
tide identification was performed using the Mascot search engine (ver. 2.3)
(Matrix Science) found in Proteome Discoverer (ver. 1.3) (Thermo Scientific)
against a composite database containing the human Uniprot database
appended with EBV and KSHV entries plus the common Repository of Ad-
ventitious Proteins database (52). All searches were carried out with cysteine
carbamidomethylation as static modification, along with methionine oxi-
dation and protein N-terminal acetylation as dynamic modifications. Spec-
tral count-based label-free quantitation was performed in Scaffold (ver. 3.0)
(Proteome Software). Peptides were confidently identified using a peptide
false-discovery-rate (FDR) of 0.01 and a protein FDR of 0.01 with at least
two unique peptides. Protein quantitation was performed by grouping
B-cell lines based on infection status or the expression status of LMP1.
Statistically significant differences in protein expression were reported by a
two-tailed ANOVA test with a P value cutoff of 0.05. Data processing, func-
tional categorization, and Kyoto Encyclopedia of Genes and Genomes path-
way analysis were performed in Perseus (ver. 1.2.0.17) (53).
IPA software was used for predicting viral specific effects on exosome
content and function and for calculating enrichment of differential gene lists
to IPA-curated Diseases and Disorder, Biological Functions, Canonical Sig-
naling Pathways, and Upstream Regulators categories. Differential gene lists
with fold changes were generated using Scaffold Q+S (Proteome Software).
2D DIGE. Exosomes were purified from the conditioned medium of cells
grown in serum-free RPMI medium for 24 h by differential centrifugation as
previously described. Proteins isolated from the concentrated exosome
pellets of two biological and technical replicates were cleaned by methanol/
chloroform precipitation and dissolved in lysis buffer [9M urea, 2M Thiourea,
20 mM Tris·HCl (pH 8.5), 2% (wt/vol) CHAPS, and 60 mM n-Octyl-β-D-gluco-
pyranoside] (54). Aliquots (15 μg) of exosome samples from biological rep-
licates of each B-cell line were labeled with 200 pmol of either Cy3 or Cy5
fluorescent dye, alternating Cy3 and Cy5 between replicates. An internal
control was prepared by pooling equal amounts of protein (7.5 μg) from all
samples which then was labeled with 200 pmol of Cy2 for every 15 μg of
protein. The labeling reaction was carried out on ice for 30 min, protected
from light. To quench the reaction, 1 μL of 10-mM lysine was added, and
then the reaction was incubated for an additional 10 min on ice in the dark.
After labeling, corresponding samples were combined so that each gel
contained an internal control (Cy2) and two samples from distinctly infected
cell lines (Cy3 and Cy5). An equal volume of 2× sample buffer [9 M urea, 2 M
Thiourea, 2% (wt/vol) CHAPS, 60 mM n-Octyl-β-D-glucopyranoside, 30 mg/mL
DTT, 2% (vol/vol) IPG buffer (pH 3–10)] was added, and the mixture was
placed on ice for 15 min. Rehydration buffer [9 M urea, 2 M Thiourea, 2%
(wt/vol) CHAPS, 60 mM n-Octyl-β-D-glucopyranoside, 15 mg/mL DTT, 2% (vol/
vol) IPG buffer (pH 3–10)] was added to a final volume of 450 μL.
The resulting mix was loaded onto an immobilized pH gradient (IPG) strip
(24 cm, pI range 3–10), and the strip was allowed to rehydrate overnight at
room temperature. Isoelectric focusing and the subsequent SDS/PAGE, using
precast 12.5% gels (Jule Biotechnologies Inc.), were performed as originally
described (55). After SDS/PAGE, gels were scanned using a Typhoon Trio Plus
scanner (GE Healthcare) and analyzed using DeCyder 7.0 software (GE
Healthcare). Enhanced statistical power (up to an n of 12) was achieved by
including biological and technical replicates and by grouping the samples
based on infection status or LMP1 expression.
EM. Aliquots of purified exosome samples were absorbed for 5 min directly
onto glow-charged thin carbon foils on 400-mesh copper grids without fix-
ation and were stained with 2% (wt/vol) uranyl acetate dissolved in water.
The grids were examined in an FEI Tecnai 12 electron microscope at 80 kV.
Images were captured on an Orius CCD Camera (Gatan) using Digital Mi-
crograph software. Images for publication were arranged and contrast op-
timized using CorelDrawX5.
Immunoblot Analysis. Cells were harvested by centrifugation at 500 × g for
5 min, washed in PBS, repelleted, and lysed with radioimmunoprecipitation
assay buffer [20 mM Tris·HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1%
Nonidet P-40, 0.1% SDS, 0.1% deoxycholic acid] supplemented with 0.5 mM
phenylmethylsulfonyl fluoride, protease, and phosphatase inhibitor mix-
tures (Sigma) and 1 mM sodium orthovanadate for 30 min on ice. Insoluble
material was removed by centrifugation for 5 min at 16,100 × g, and equal
amounts of soluble protein were mixed with 5X Laemmli sample buffer and
subjected to immunoblot analysis as previously described (56). Equal protein
loading was confirmed by Ponceau S (Sigma) staining of blots before
blocking. Similarly, lysates from purified exosomes were mixed with Laemmli
sample buffer before SDS/PAGE and immunoblot analysis. Primary anti-
bodies used include LANA (Advanced Biotechnologies), EBNA2 (PE2), LMP1
(CS1-4; Dako), LMP2A (Thermo), GAPDH (Santa Cruz), tumor susceptibility
gene 101 (TSG101) (Santa Cruz), CD63, Flotillin 2 (Cell Signaling), and Ezrin
(Cell Signaling).
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